Document is current
Any future updates will be listed below
-
Authors
Daneshmandi, Saeed https://orcid.org/0000-0001-7817-3006
Yan, Qi
Gomez, Eduardo Cortes https://orcid.org/0000-0002-0966-6488
Choi, Jee Eun https://orcid.org/0000-0002-9221-0181
Katsuta, Eriko https://orcid.org/0000-0001-5862-2919
Gharib, Ehsan
Singh, Prashant K.
Higashi, Richard M. https://orcid.org/0000-0002-3256-0622
Lane, Andrew N. https://orcid.org/0000-0003-1121-5106
Fan, Teresa W-M.
Wang, Jianmin https://orcid.org/0000-0001-7527-0409
Repasky, Elizabeth A.
McCarthy, Philip L. https://orcid.org/0000-0002-9577-3879
Mohammadpour, Hemn https://orcid.org/0000-0002-0158-7283
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (R00 HL155792)
V Foundation for Cancer Research
Roswell Park Alliance Foundation, Roswell Park Cancer Institute
- License Information
-
More Information
Article History
Received: 3 July 2025
Accepted: 18 December 2025
First Online: 14 January 2026
Competing interests
: Advisory Board/Consulting for P.L.M.: BlueBird Biotech, Bristol-Myers Squibb, Celgene, Fate Therapeutics, Janssen, Juno, Karyopharm, Magenta Therapeutics, Sanofi, and Takeda. Honoraria for P.L.M.: BlueBird Biotech, Bristol-Myers Squibb, Celgene, Fate Therapeutics, Janssen, Juno, Karyopharm, Magenta Therapeutics, Sanofi, and Takeda. Other authors declare no competing interests.
